Form 4: Xenon Pharmaceuticals' Chief Legal Officer Granted Stock Options
SEC Form 4 Filing
Andrea DiFabio, Chief Legal Officer of Xenon Pharmaceuticals, was granted stock options for 100,000 common shares on March 11, 2024, according to a Form 4 filing.
Summary
- Andrea DiFabio, the Chief Legal Officer of Xenon Pharmaceuticals Inc., was granted stock options on March 11, 2024.
- The options are for 100,000 common shares of Xenon Pharmaceuticals.
- The exercise price of the options is $44.37.
- The options vest 25% on January 1, 2025, and the remaining 75% vest over the following three years in equal monthly installments.
- The options expire on March 10, 2034.
- A Power of Attorney was executed on March 8, 2024, granting Sherry Aulin, Ilona Lo, and Nathaniel Adams the authority to act on Andrea DiFabio's behalf for SEC filings.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports a standard executive compensation practice. It's neither overwhelmingly positive nor negative.
Positives
- The granting of stock options to a key executive like the Chief Legal Officer can be seen as a positive sign, aligning their interests with the company's long-term success.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the granting of stock options suggests an expectation of future value creation.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize and retain key executives. This aligns with standard compensation practices in the sector.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry.
- Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options to incentivize their executives.
- The vesting schedule and exercise price are within the typical range observed for similar grants in comparable companies.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the Chief Legal Officer to contribute to the company's success.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 2024-03-08 | Date of Power of Attorney execution. |
| 2024-03-11 | Date of stock option grant. |
| 2024-03-12 | Date of Form 4 filing. |
| 2025-01-01 | Initial vesting date (25%) of the stock options. |
| 2034-03-10 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.